(July 18, 2016) The first randomized phase III clinical trial to compare irinotecan and cisplatin with paclitaxel plus carboplatin in patients with clear cell carcinoma (CCC) of the ovary found no significant survival benefit between the groups. The findings of the study, which was conducted in Japan, were reported in the Journal of Clinical Oncology.
With a median follow-up of 44.3 months, 2-year progression-free survival rates were 73.0% in the irinotecan-plus-cisplatin group and 77.6% in the paclitaxel-plus-carboplatin group. Two-year overall survival rates were 85.5% with and 87.4% respectively.
Both regimens were well tolerated and no treatment-related deaths were reported, although the toxicity profiles differed.
